dAIALS: Personalized Lab-on-a-Chip Diagnostics for Early ALS Detection
Advancing dAIgnostics’ ALS platform toward clinical and market readiness
dAIALS develops an integrated diagnostic-support workflow for early and personalized ALS detection. The project combines NIMOCHIP™, microfluidics, fluorescent optical recording, cellular calcium analysis and AI-powered data processing to support earlier and more precise ALS diagnostics.
Challenge
ALS diagnosis is often delayed until symptoms are already pronounced, limiting timely intervention and patient stratification. Earlier diagnostic support requires a workflow that captures functional disease-related signals and translates them into clinically meaningful insight.
Solution
dAIALS supports an integrated lab-on-a-chip and AI-powered diagnostic workflow:
Patient-derived IgG → NIMOCHIP™ → Living-cell response → Optical recording → AI-supported insight. The project brings together biological testing, microfluidics, optical recording and digital analysis in a modular architecture for clinical and commercial translation.
What dAIALS develops
Lab-on-a-chip workflow
NIMOCHIP™-based testing and fluorescent optical recording for controlled analysis of living-cell responses.
AI and data modules
dAI Connect, dAI Parse and dAI Detect for secure data transfer, metadata structuring and disease-related pattern recognition.
Explainable reporting
dAI Explain for translating analytical outputs into clear diagnostic-support reports.
Role within the dAIgnostics platform
dAIALS connects the full diagnostic-support workflow, from patient-derived IgG and living-cell testing to optical recording, AI interpretation and explainable reporting.
Patient-derived IgG
NIMOCHIP™A
Living-cell response
Optical recording
Al-supported insight
Diagnostic-support report
Project funding information
The project “dAIgnostics method for early and personalized diagnosis of amyotrophic lateral sclerosis – dAIALS” is co-funded by the European Union under the Competitiveness and Cohesion Programme 2021–2027, Call “Innovations of Newly Established SMEs”, call code PK.1.1.08.
- Project beneficiary: DAIGNOSTICS d.o.o.
- Project code: PK.1.1.08.0182
- Implementation period: 18 months from 1st January 2026 – 1st July 2027
Project description
The aim of the dAIALS project is to develop an innovative method for early and personalized diagnosis of amyotrophic lateral sclerosis, based on cellular calcium analysis, microfluidics, artificial intelligence and cloud computing.
Expected project result
The expected result of the project is the development and validation of an MVP solution that enables further preparation for commercialization and future application in early and personalized ALS diagnostics.